Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Home
/
update
/
details

MGI Partners with OncoDNA to Enhance Precision Oncology with Compatible Genomic Solutions

NextEdge Admin

29 Oct 2024

2 min 22 sec

OncoDNA,Precision Oncology,Comprehensive Genomic Profiling

MGI Tech Co., Ltd. (MGI), a leader in life science innovations, announced a new collaboration with OncoDNA, a genomic and theranostic company focused on precision medicine for cancer and genetic disease treatment. The partnership ensures full compatibility between OncoDNA’s OncoDEEP® Kit and MGI’s advanced DNBSEQ™ sequencing platforms.

The OncoDEEP® Kit offers a comprehensive end-to-end workflow, including sequencing, secondary analysis, and interpretation using OncoKDM™. By making the solution technology-neutral, OncoDNA aims to expand setup options for laboratories previously reliant on a single sequencing provider. Now, laboratories can leverage MGI’s DNBSEQ™ technology to perform solid tumor Comprehensive Genomic Profiling (CGP) with enhanced efficiency and accuracy.

DNBSEQ™ technology utilizes DNA nanoballs (DNBs) on Patterned Array chips, improving sequencing accuracy, sensitivity, and reducing amplification bias. This cutting-edge approach aligns with the precision oncology goals of OncoDEEP®, whose CGP panel covers 638 genes across 1.8 Mb. It supports key biomarkers like Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), Loss of Heterozygosity (LOH), and Homologous Recombination Deficiency (HRD).

Presented at the 36th European Congress of Pathology, the collaboration highlights the OncoDEEP® Kit’s clinical insights on MGI platforms.

“Partnering with MGI strengthens our mission to make precision oncology accessible to all,” said Jean-Pol Detiffe, Founder of OncoDNA. “This collaboration enhances genomic profiling and expands technology options for labs.”

Dr. Yong Hou, GM of MGI EU & Africa, added, “We are proud to support better, faster results with this partnership, offering more applications in somatic genomics.”